Preclinical evidence supports that combining KRAS G12C inhibitors with CDK4/6 inhibitors could yield synergistic antitumor effects in NSCLC, colorectal, pancreatic, and oesophagal cancers, particularly when cell cycle control is compromised due to CDKN2A/B deletion or p16 inactivation [53,54]. Here, CDK4 is linked to non-small cell lung carcinoma.